CBD Combined With Nitroprusside Prevented Schizophrenia-Like Symptoms in Rats, With Sex Differences

Rats pretreated with CBD and sodium nitroprusside (SNP) during brain development (postnatal days 12-32) and later challenged with ketamine showed sex-dependent responses. Females showed greater hyperlocomotion and long-term memory deficits; males showed reduced sucrose preference and short-term memory impairments. CBD or SNP alone had limited efficacy, but their combination reduced hyperlocomotion and prevented memory deficits in both sexes, with superior effects in females.

Wistar rats were pretreated with CBD and SNP (alone or combined) during postnatal days 12-32. After 10 days, schizophrenia-like deficits were induced with ketamine. Behaviors were assessed using Open Field Test (locomotion), Sucrose Preference Test (anhedonia), and Novel Object Recognition (memory). Multivariate analysis and unsupervised clustering examined sex differences.

This is the first preclinical evidence of sex-dependent prophylactic effects of CBD combined with nitroprusside in a schizophrenia model. The finding that early intervention during brain development could prevent later psychosis-like symptoms opens new thinking about preventive approaches.

Schizophrenia treatments are largely reactive rather than preventive. This animal study suggests that early CBD intervention during critical brain development windows might prevent psychosis-like symptoms from emerging, though translating this concept to human prevention would require extensive further research.

Animal study in rats; results may not translate to humans. Ketamine model only approximates some features of schizophrenia. CBD and SNP doses and timing in rats cannot be directly translated to human developmental periods. Did not examine long-term outcomes or potential side effects of early-life cannabinoid exposure.